Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prognostic and Diagnostic Value of Node-RADS for Non-Small Cell Lung Cancer Following Neoadjuvant Therapy: A Multicenter Cohort Study.

Diagnostics (Basel, Switzerland)·2026
Same author

An explainable multimodal 2.5D deep learning-radiomics model for predicting extranodal extension in lung adenocarcinoma using preoperative CT: a multicenter retrospective cohort study.

BMC medical imaging·2026
Same author

Integrating AI-driven single-cell analysis to decode epithelial heterogeneity: A prognostic signature and translational immunotherapy strategy targeting <i>KRT18</i>-induced PD-L1 in lung adenocarcinoma.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu·2026
Same author

Correction: Integrative multi-omics and machine learning reveals the spatial niche distribution and role of CYP27A1+TAMs in immunotherapy response in non-small cell lung cancer.

Frontiers in immunology·2026
Same author

Risk stratification in stage I invasive non-mucinous lung adenocarcinoma based on high-risk histopathologic features.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Response-Adapted Benefit of Postoperative Adjuvant Therapy Following Neoadjuvant Treatment in Resectable NSCLC: A Single-Center Retrospective Cohort Study.

Cancers·2026

相关实验视频

Updated: Jan 12, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K

在EGFR突变的LUAD中,通过单细胞转录组学和多算法机器学习进行恶性上皮细胞程序的综合建模.

Weiran Zhang1, Lin Tan2, Qiuqiao Mu1

  • 1Tianjin Chest Hospital, Tianjin University, Tianjin, China.

Frontiers in immunology
|October 30, 2025
PubMed
概括

这项研究确定了EGFR突变肺腺癌 (LUAD) 细胞中的关键恶性特征. 一个新的预后签名,EGFRmERS,预测存活率和免疫治疗反应,突出显示PERP是LUAD患者潜在的治疗标.

关键词:
欧洲农业基金会 (EGFR) 是一个基金.卢阿德 (Luad) 的意思是说.在 PERP PERP 里面.免疫疗法 免疫疗法机器学习是机器学习.这就是scRNA-seqq.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

相关实验视频

Last Updated: Jan 12, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

科学领域:

  • 在瘤学瘤学.
  • 基因组学就是基因组学.
  • 生物信息学是一种生物信息学.

背景情况:

  • 肺腺癌 (LUAD) 是一种常见的非小细胞肺癌亚型,由EGFR突变驱动.
  • 患者的治疗结果和治疗反应存在显著的异质性,需要更好的分层方法.
  • 鉴别EGFR突变表皮细胞的恶性特征对于个性化治疗策略至关重要.

研究的目的:

  • 使用单细胞RNA测序,识别和描述EGFR突变LUAD上皮细胞中的恶性程序.
  • 开发一个强大的预后特征 (EGFRmERS) 来预测患者的存活率和免疫治疗反应.
  • 在EGFR突变LUAD中识别潜在的治疗点.

主要方法:

  • 单细胞RNA测序数据分析,以识别恶性上皮细胞并构建假名时间轨迹.
  • 机器学习算法应用于转录基因数据,以开发EGFRmERS预后签名.
  • 在独立队列中验证EGFRmERS,并评估其与免疫透,TMB和CNV的关联.
  • 在实验室中对核心基因PERP的功能验证.

主要成果:

  • EGFR突变的上皮细胞被分类为具有明显恶性潜力的子集群和丰富的途径.
  • 开发的EGFRmERS签名显示出强大的预测价值,并且表现优于现有模型.
  • 高EGFRmERS分数与免疫抑制性瘤微环境,免疫治疗反应减少,TMB升高和基因组不稳定性相关.
  • 鉴定出PERP基因是LUAD恶性瘤的关键驱动因素,促进细胞迁移,入侵和殖民地形成.

结论:

  • 该研究提出了一个新的预后签名,EGFRmERS,用于精确分层和预测EGFR突变LUAD治疗效益.
  • EGFRmERS为推动LUAD进展的分子机制提供了宝贵的见解,并可以指导个性化治疗策略.
  • PERP成为改善EGFR突变LUAD结果的有希望的治疗标.